Drug
Bmn 349
Bmn 349: highest development phase Phase 1, developed by BioMarin Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- BioMarin Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| BMN 349 NCT06738017 | Phase 1 | Alpha 1-Antitrypsin Deficiency |
Latest
No recent events.
Follow Bmn 349 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.